array:19 [
  "pii" => "X0211699500025427"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:75"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1634
    "formatos" => array:3 [
      "EPUB" => 163
      "HTML" => 1192
      "PDF" => 279
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025419"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:76"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1444
      "formatos" => array:3 [
        "EPUB" => 154
        "HTML" => 1019
        "PDF" => 271
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "«HIPERTENSIÓN Y ENFERMEDAD CARDIOVASCULAR EN PACIENTES CON INSUFICIENCIA RENAL CRÓNICA» Effects of hyperparathyroidism in the pathogenesis of hypertension, left ventricular hypertrophy and cardiovascular disease in CRF patients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "76"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "T. B. DRÜEKE"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "T. B. DRÜEKE"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025419?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025419/v0_201502091333/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025435"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:73-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2546
      "formatos" => array:3 [
        "EPUB" => 166
        "HTML" => 2049
        "PDF" => 331
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Tratamiento de la hipertensión después del trasplante renal con antagonistas de los Receptores de la Angiotensina"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "73"
          "paginaFinal" => "74"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "D. DEL CASTILLO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "D. DEL CASTILLO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025435?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025435/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "«NEFROPATÍA DIABÉTICA TIPO II: LA EPIDEMIA DEL SIGLO XXI» New approaches to primary and secondary prevention of diabetic nephropathy"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "75"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "G. REMUZZI"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "G. REMUZZI"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 «NEFROPATÍA DIABÉTICA TIPO II: LA EPIDEMIA DEL SIGLO XXI» New approaches to primary and secondary prevention of diabetic nephropathy G. Remuzzi, MD About 30% of insulin dependent diabetic (IDD) and 15-60% of non-insulin-dependent diabetic (NIDD) patients develop diabetic nephropathy (DN), a syndrome of macroalbuminuria, systemic hypertension and declining glomerular filtration rate (GFR), associated with a 20 to 40-fold increased risk of cardiovascular mortality. DN, the leading cause of end stage renal failure in Western countries, is invariably heralded by the appearance of persistent microalbuminuria (incipient nephropathy: IN). Every year, 4.4% to 6.8% of IDD patients on conventional insulin therapy and 4.6% of NIDD patients progress to micro-albuminuria. A higher rate of progression is reported in smokers and in patients with higher blood pressure. Thus, microalbuminuria is now considered an early marker of renal involvement in diabetes, and its prevention can be taken as to indicate primary prevention of DN. It is well established that angiotensin converting enzyme (ACE) inhibitors delay the progression of IN to overt DN (secondary prevention) either in IDD and in NIDD and remarkably decrease disease progression to uremia and overall cardiovascular mortality in IDD patients with overt DN. Whether early treatment with ACE inhibitors in normoalbuminuric diabetic patients may effectively prevent progression to microalbuminuria (primary prevention) is not established so far. However, preliminary evidence is available that the incidence of microalbuminuria may be reduced by ACE inhibition therapy in hypertensive NIDD patients. Calcium channel blockers (CCBs) inhibit the vasoconstrictor as well as both the hypertrophic and hyperplastic effects of angiotensin II and other mytogens on mesangial and vascular smooth muscle cells through blockade of calcium dependent mechanisms. Early studies, however, demonstrate marked differences between the antiproteinuric effects of dihydropyridine CCBs and nondihydropyridine CCBs, such as verapamil and diltiazem. Recent data support the concept that differences in antiproteinuric response subclasses relate to their differential effects on glomerular permeability, that is, dihydropyridine CCBs do not ameliorate glomerular barrier perm-selectivity whereas nondihydropyridine CCBs attenuate it. Failure to restore the sieving properties of the glomerular barrier increases protein ultrafiltration and enhanced protein traffic in the long-term contributes to the progression of renal injury independently of the underlying renal disease. Recent studies found that nondihydropyridine CCBs may have the same reno-protective potential of ACE inhibitors either in experimental models of progressive renal disease and in NIDD patients. The association of ACE inhibitors with nondihydropyridine CCBs may even more effectively than the two agents alone decrease, at comparable level of blood pressure control, proteinuria and prevent glomerulosclerosis in experimental diabetes and in hypertensive stroke-prone rats. Additionally, recent studies document that the association of ACE inhibitors with nondihydropyridine CCBs reduces urinary albumin excretion rate more effectively than the two agents alone in hypertensive NIDDM patients either with incipient or overt nephropathy. Furthermore, in proteinuric NIDDM patients, the combination of these classes of agents appears to slow GFR decline and to yield the lowest side effect profile over either agent alone in diabetic patients with overt nephropathy. Lastly, the association of a calcium channel blocker to ACE inhibition therapy in hypertensive diabetics may reduce the need for additional diuretic therapy that has been associated with an excess mortality in diabetic mellitus. However, whether the association may more effectively than ACE inhibitors alone prevent the onset of microalbuminuria (primary prevention) or delay the progression from microalbuminuria to macroalbuminuria (secondary prevention) is not established so far. 75 "
    "pdfFichero" => "P7-E170-S140-A1912.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025427/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025427/v0_201502091333/en/P7-E170-S140-A1912.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025427?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

«NEFROPATÍA DIABÉTICA TIPO II: LA EPIDEMIA DEL SIGLO XXI» New approaches to primary and secondary prevention of diabetic nephropathy
G. REMUZZI
Leído
4324
Veces
se ha leído el artículo
1599
Total PDF
2725
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699500025427"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:75"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1634
    "formatos" => array:3 [
      "EPUB" => 163
      "HTML" => 1192
      "PDF" => 279
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025419"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:76"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1444
      "formatos" => array:3 [
        "EPUB" => 154
        "HTML" => 1019
        "PDF" => 271
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "«HIPERTENSIÓN Y ENFERMEDAD CARDIOVASCULAR EN PACIENTES CON INSUFICIENCIA RENAL CRÓNICA» Effects of hyperparathyroidism in the pathogenesis of hypertension, left ventricular hypertrophy and cardiovascular disease in CRF patients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "76"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "T. B. DRÜEKE"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "T. B. DRÜEKE"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025419?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025419/v0_201502091333/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025435"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:73-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2546
      "formatos" => array:3 [
        "EPUB" => 166
        "HTML" => 2049
        "PDF" => 331
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Tratamiento de la hipertensión después del trasplante renal con antagonistas de los Receptores de la Angiotensina"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "73"
          "paginaFinal" => "74"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "D. DEL CASTILLO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "D. DEL CASTILLO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025435?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025435/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "«NEFROPATÍA DIABÉTICA TIPO II: LA EPIDEMIA DEL SIGLO XXI» New approaches to primary and secondary prevention of diabetic nephropathy"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "75"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "G. REMUZZI"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "G. REMUZZI"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 «NEFROPATÍA DIABÉTICA TIPO II: LA EPIDEMIA DEL SIGLO XXI» New approaches to primary and secondary prevention of diabetic nephropathy G. Remuzzi, MD About 30% of insulin dependent diabetic (IDD) and 15-60% of non-insulin-dependent diabetic (NIDD) patients develop diabetic nephropathy (DN), a syndrome of macroalbuminuria, systemic hypertension and declining glomerular filtration rate (GFR), associated with a 20 to 40-fold increased risk of cardiovascular mortality. DN, the leading cause of end stage renal failure in Western countries, is invariably heralded by the appearance of persistent microalbuminuria (incipient nephropathy: IN). Every year, 4.4% to 6.8% of IDD patients on conventional insulin therapy and 4.6% of NIDD patients progress to micro-albuminuria. A higher rate of progression is reported in smokers and in patients with higher blood pressure. Thus, microalbuminuria is now considered an early marker of renal involvement in diabetes, and its prevention can be taken as to indicate primary prevention of DN. It is well established that angiotensin converting enzyme (ACE) inhibitors delay the progression of IN to overt DN (secondary prevention) either in IDD and in NIDD and remarkably decrease disease progression to uremia and overall cardiovascular mortality in IDD patients with overt DN. Whether early treatment with ACE inhibitors in normoalbuminuric diabetic patients may effectively prevent progression to microalbuminuria (primary prevention) is not established so far. However, preliminary evidence is available that the incidence of microalbuminuria may be reduced by ACE inhibition therapy in hypertensive NIDD patients. Calcium channel blockers (CCBs) inhibit the vasoconstrictor as well as both the hypertrophic and hyperplastic effects of angiotensin II and other mytogens on mesangial and vascular smooth muscle cells through blockade of calcium dependent mechanisms. Early studies, however, demonstrate marked differences between the antiproteinuric effects of dihydropyridine CCBs and nondihydropyridine CCBs, such as verapamil and diltiazem. Recent data support the concept that differences in antiproteinuric response subclasses relate to their differential effects on glomerular permeability, that is, dihydropyridine CCBs do not ameliorate glomerular barrier perm-selectivity whereas nondihydropyridine CCBs attenuate it. Failure to restore the sieving properties of the glomerular barrier increases protein ultrafiltration and enhanced protein traffic in the long-term contributes to the progression of renal injury independently of the underlying renal disease. Recent studies found that nondihydropyridine CCBs may have the same reno-protective potential of ACE inhibitors either in experimental models of progressive renal disease and in NIDD patients. The association of ACE inhibitors with nondihydropyridine CCBs may even more effectively than the two agents alone decrease, at comparable level of blood pressure control, proteinuria and prevent glomerulosclerosis in experimental diabetes and in hypertensive stroke-prone rats. Additionally, recent studies document that the association of ACE inhibitors with nondihydropyridine CCBs reduces urinary albumin excretion rate more effectively than the two agents alone in hypertensive NIDDM patients either with incipient or overt nephropathy. Furthermore, in proteinuric NIDDM patients, the combination of these classes of agents appears to slow GFR decline and to yield the lowest side effect profile over either agent alone in diabetic patients with overt nephropathy. Lastly, the association of a calcium channel blocker to ACE inhibition therapy in hypertensive diabetics may reduce the need for additional diuretic therapy that has been associated with an excess mortality in diabetic mellitus. However, whether the association may more effectively than ACE inhibitors alone prevent the onset of microalbuminuria (primary prevention) or delay the progression from microalbuminuria to macroalbuminuria (secondary prevention) is not established so far. 75 "
    "pdfFichero" => "P7-E170-S140-A1912.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025427/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025427/v0_201502091333/en/P7-E170-S140-A1912.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025427?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 7 13 20
2024 Octubre 50 33 83
2024 Septiembre 48 29 77
2024 Agosto 64 54 118
2024 Julio 36 38 74
2024 Junio 47 33 80
2024 Mayo 63 40 103
2024 Abril 41 23 64
2024 Marzo 40 22 62
2024 Febrero 37 32 69
2024 Enero 25 21 46
2023 Diciembre 27 28 55
2023 Noviembre 33 28 61
2023 Octubre 27 34 61
2023 Septiembre 29 27 56
2023 Agosto 29 29 58
2023 Julio 38 27 65
2023 Junio 41 17 58
2023 Mayo 39 30 69
2023 Abril 21 18 39
2023 Marzo 16 17 33
2023 Febrero 19 18 37
2023 Enero 23 25 48
2022 Diciembre 30 19 49
2022 Noviembre 21 21 42
2022 Octubre 26 40 66
2022 Septiembre 24 24 48
2022 Agosto 26 39 65
2022 Julio 28 37 65
2022 Junio 27 23 50
2022 Mayo 20 24 44
2022 Abril 29 31 60
2022 Marzo 26 42 68
2022 Febrero 22 41 63
2022 Enero 20 23 43
2021 Diciembre 13 32 45
2021 Noviembre 28 26 54
2021 Octubre 36 37 73
2021 Septiembre 15 24 39
2021 Agosto 18 17 35
2021 Julio 31 28 59
2021 Junio 14 7 21
2021 Mayo 24 16 40
2021 Abril 29 22 51
2021 Marzo 27 11 38
2021 Febrero 23 8 31
2021 Enero 15 9 24
2020 Diciembre 17 12 29
2020 Noviembre 9 5 14
2020 Octubre 13 2 15
2020 Septiembre 8 0 8
2020 Agosto 17 5 22
2020 Julio 12 7 19
2020 Junio 16 6 22
2020 Mayo 15 9 24
2020 Abril 28 14 42
2020 Marzo 12 11 23
2020 Febrero 25 18 43
2020 Enero 34 13 47
2019 Diciembre 17 6 23
2019 Noviembre 8 1 9
2019 Octubre 8 3 11
2019 Septiembre 7 15 22
2019 Agosto 8 7 15
2019 Julio 14 11 25
2019 Junio 9 7 16
2019 Mayo 8 8 16
2019 Abril 26 29 55
2019 Marzo 14 8 22
2019 Febrero 6 13 19
2019 Enero 14 8 22
2018 Diciembre 24 17 41
2018 Noviembre 34 9 43
2018 Octubre 36 10 46
2018 Septiembre 18 4 22
2018 Agosto 21 11 32
2018 Julio 18 7 25
2018 Junio 11 6 17
2018 Mayo 16 9 25
2018 Abril 15 4 19
2018 Marzo 14 3 17
2018 Febrero 16 4 20
2018 Enero 9 3 12
2017 Diciembre 10 4 14
2017 Noviembre 14 7 21
2017 Octubre 12 3 15
2017 Septiembre 7 3 10
2017 Agosto 16 6 22
2017 Julio 6 3 9
2017 Junio 10 13 23
2017 Mayo 4 1 5
2017 Abril 4 1 5
2017 Marzo 6 2 8
2017 Febrero 5 1 6
2017 Enero 2 1 3
2016 Diciembre 7 2 9
2016 Noviembre 17 3 20
2016 Octubre 41 4 45
2016 Septiembre 36 1 37
2016 Agosto 34 2 36
2016 Julio 48 0 48
2016 Junio 73 0 73
2016 Mayo 84 0 84
2016 Abril 38 0 38
2016 Marzo 35 0 35
2016 Febrero 29 0 29
2016 Enero 30 0 30
2015 Diciembre 44 0 44
2015 Noviembre 37 0 37
2015 Octubre 26 0 26
2015 Septiembre 34 0 34
2015 Agosto 19 0 19
2015 Julio 27 0 27
2015 Junio 8 0 8
2015 Mayo 13 0 13
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?